Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.
9 of 12 patients with advanced metastatic carcinoma of the prostate treated with luteinising-hormone-releasing-hormone (LHRH) analogue ICI 118630 for a mean period of 6 months showed objective evidence of response to treatment. Of 8 patients with bone pain, 7 obtained relief. After 6 weeks of treatment testosterone concentrations were reduced to castrate levels (range less than 2 to 5.5 nmol/l) from a pretreatment mean value of 15.7 nmol/l (range 10.3-24 nmol/l). Basal gonadotropin levels and gonadotropin responses to acute LHRH stimulation were suppressed within 2 weeks of treatment. However, the testosterone response to stimulation with human chorionic gonadotropin was unimpaired 4 weeks after the start of treatment. Therefore suppression of the basal testosterone concentration by ICI 118630 was due to inhibition of pituitary luteinising-hormone secretion rather than direct inhibition of testicular Leydig-cell function. ICI 118630 offers an alternative treatment to orchidectomy and oestrogen therapy.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D006063:Chorionic Gonadotropin / Q000378:metabolism; D003864:Depression, Chemical; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017273:Goserelin; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010388:Pelvis / Q000000981:diagnostic imaging; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011859:Radiography; D013739:Testosterone / Q000097:blood
D006063:Chorionic Gonadotropin; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D000135:Acid Phosphatase